Overview

Safety and Pharmacokinetics of Quinidine Alone and in Combination With Dabigatran Etexilate

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Open-label, two-way crossover design with a quinidine sulfate run-in period followed by a randomised sequence of dabigatran etexilate plus quinidine sulfate or dabigatran etexilate alone to evaluate the safety of co-administration of dabigatran etexilate and quinidine. and the pharmacokinetic interaction between quinidine and dabigatran etexilate.
Phase:
Phase 1
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Dabigatran
Quinidine
Quinidine gluconate